Abbott
Abbott Laboratories, commonly known as Abbott, is a leading global healthcare company headquartered in the United States. Founded in 1888, Abbott has established a strong presence in various operational regions, including North America, Europe, and Asia. The company operates primarily in the medical devices, diagnostics, nutrition, and pharmaceuticals sectors. Abbott is renowned for its innovative products, such as the FreeStyle Libre glucose monitoring system and Similac infant formula, which set industry standards for quality and effectiveness. With a commitment to advancing health and well-being, Abbott has achieved significant milestones, including the rapid development of COVID-19 testing solutions. As a market leader, Abbott consistently ranks among the top healthcare companies worldwide, recognised for its dedication to research and development, and its ability to deliver cutting-edge solutions that improve patient outcomes.
DitchCarbon Score
How does Abbott's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbott's score of 65 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abbott's reported carbon emissions
In 2023, Abbott reported significant carbon emissions, totalling approximately 1,510,000,000 kg CO2e globally. This includes 510,000,000 kg CO2e from Scope 1 emissions and 407,000,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets to reduce its absolute Scope 1 and 2 emissions by 30% by 2030, using 2018 as the baseline year. This commitment aligns with the Science Based Targets initiative (SBTi) and aims to contribute to limiting global warming to well below 2°C. Abbott's emissions reduction strategy includes operational energy efficiency, purchasing renewable energy, electrifying industrial processes, and integrating sustainable engineering technologies. The company also aims for 82% of its suppliers, by emissions, to have science-based targets by 2026. In addition to its near-term goals, Abbott has committed to achieving net-zero emissions by 2050, further demonstrating its dedication to sustainability and climate action. The company’s efforts reflect a comprehensive approach to reducing its carbon footprint while maintaining its operational integrity in the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 620,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 648,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbott is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
